Business
Hydreight Technologies Enters the At-Home STI Testing Market With Exclusive Distribution and 50,000 Pre-Orders
VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ( ...
About this update from Hydreight Technologies Inc
[{"type":"text","content":"Hydreight Technologies Enters the At-Home STI Testing Market With Exclusive Distribution and 50,000 Pre-Orders\nVANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”), a digital health platform enabling on-demand care, pharmacy fulfillment, and enterprise healthcare services across the United States, today announced its entry into the rapidly expanding at-home sexually transmitted infection (“STI”) pre-screening market through an exclusive distribution agreement with Health Screen Collective (“HSC”). Under the agreement, Hydreight will serve as the exclusive distributor of HSC’s at-home STI pre-screen testing kits across its national platform. The Company has already secured approximately 50,000 pre-orders, with deliveries expected to begin in early 2026. A Widespread, Under-Diagnosed Public Health Reality Sexually transmitted infections represent one of the most prevalent and under-diagnosed healthcare challenges in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately one in five people in the U.S. is living with an STI at any given time, with tens of millions of new infections occurring annually. Despite this prevalence, a significant portion of infections remain undiagnosed due to stigma, inconvenience, cost, and long wait times associated with traditional clinic-based testing. Globally, the World Health Organization (WHO) estimates that more than one million curable STIs are acquired every day, underscoring the scale of the issue and the growing need for accessible, private screening solutions. Testing in Minutes, Not Days HSC’s at-home STI pre-screen testing kits are designed to deliver results in minutes rather than days, enabling faster awareness and earlier engagement with care. Using validated lateral-flow immunoassay technology, the kits allow individuals to collect samples privately at home through clear, step-by-step instructions, eliminating the need for clinic visits or laboratory processing delays at the initial screening stage. Depending on the selected panel, the kits provide pre-screening for multiple common infections, including: Chlamydia trachomatisNeisseria gonorrhoeaeTrichomonas vaginalisMycoplasma genitaliumCandida albi...